Description
Thymosin Alpha-1 (also known as Tα1, Thymalfasin, or Zadaxin) is a synthetic 28-amino acid polypeptide with a molecular weight of approximately 3108 Da . It was first isolated from thymosin fraction 5, a bovine thymus extract, and was chemically synthesized in 1980 . The peptide has an isoelectric point of 4.2 and exists as a white to off-white lyophilized powder .
This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.
Key Research Focus
Thymosin Alpha-1 has been investigated in preclinical and clinical research exploring its roles in:
- T-Cell Maturation and Differentiation: Tα1 induces the expression of Thy-1, CD5, and CD8 on thymocytes and enhances mitogenic, cytokine, and antibody responses of lymphocytes in vitro . It promotes T-cell differentiation and maturation, with CD4+, CD8+, and CD3+ cells all shown to be increased .
- Cytokine Production and NK Cell Activation: Tα1 increases production of IFN-γ, IL-2, and IL-3, and enhances expression of the IL-2 receptor following activation by mitogens or antigens . It also activates natural killer (NK) cell-mediated cytotoxicity and increases antibody response to T-cell dependent antigens . The peptide has been shown to modulate an early event during lymphocyte activation, with a 30-minute preincubation sufficient to enhance IL-2 production and IL-2R expression .
- Toll-Like Receptor Signaling: Tα1 has been shown to upregulate expression of Toll-like receptors (TLR2 and TLR9) in mouse and human dendritic cells, as well as activate NF-κB and JNK/P38/AP1 pathways . This provides a mechanistic basis for its immunomodulatory and antiviral effects.
- Hematopoietic Effects: In nu/nu mice, Tα1 enhanced hematopoietic colony formation (CFU-s, GM-CFU, T-CFU) and stimulated IL-3 production, suggesting indirect effects on hematopoietic stem cells through cytokine-mediated pathways .
Clinical Research Landscape
Thymosin Alpha-1 has been evaluated across diverse clinical indications:
- Chronic Hepatitis B: Early randomized trials in China demonstrated that Zadaxin (Tα1) was effective in inhibiting HBV replication and produced higher seroconversion rates compared to IFN-α . However, a Cochrane review concluded that Tα1 may have little to no effect on histological improvement, with evidence certainty rated as very low due to high risk of bias and imprecision .
- Sepsis (TESTS Trial): A 2025 multicentre, double-blind, randomized, placebo-controlled Phase 3 trial (n=1106) evaluated Tα1 (1.6 mg SC every 12 hours for 7 days) in adults with sepsis. The trial found no clear evidence that Tα1 decreases 28-day all-cause mortality (23.4% vs 24.1%, HR 0.99, P=0.93). Prespecified subgroup analysis suggested potential differential effects by age (<60 years: HR 1.67; ≥60 years: HR 0.81; P for interaction=0.01) and diabetes (diabetes: HR 0.58; no diabetes: HR 1.16; P for interaction=0.04) .
- Cancer Immunotherapy: An ongoing Phase 2 trial (NCT07644897) is evaluating Tα1 combined with anti-PD-1 monoclonal antibody (Toripalimab) in elderly patients (≥60 years) with advanced melanoma. Tα1 is administered at 1.6 mg SC daily for 7 days, then three times weekly, with the primary endpoint being objective response rate . Earlier Phase 2 studies in unresectable hepatocellular carcinoma showed numerically higher response rates with TACE plus Tα1 versus TACE alone (57.1% vs 45.5%), with median OS of 110.3 vs 57.0 weeks, though differences did not reach statistical significance .
- Vaccine Enhancement: Tα1 is under investigation as an enhancer of vaccine response in older adults (≥65 years) receiving COVID-19 booster doses (NCT06821100). The FDA has approved Tα1 as an adjuvant for influenza vaccine in elderly patients and for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers .
Pharmacokinetics
- Absorption: Rapidly absorbed following subcutaneous administration, with peak serum levels achieved at approximately 2 hours .
- Half-Life: Approximately 2 hours. No evidence of accumulation following multiple subcutaneous doses .
- Biodistribution: In mice, Tα1 concentrations increased significantly in thymus, lungs, spleen, kidneys, ovaries, and peritoneal fat within 40 minutes of intraperitoneal administration. No significant increases were detected in brain, skeletal muscle, liver, or heart. Rapid renal excretion represents a major route of elimination .
Safety Considerations (Research Context)
The FDA has identified immunogenicity and aggregation concerns for Tα1 when administered via injectable routes. Peptides administered via subcutaneous and intramuscular routes may pose a significant risk for immunogenicity, potentially amplified by aggregation and peptide-related impurities. No CoA for Tα1 (free base) in the nomination package contained information about impurity limits or testing results to demonstrate quality control of the impurity profile, and information on peptide aggregation potential is lacking . No clinical studies assessing immunogenicity or aggregation of Tα1 have been identified.
Regulatory Status
Tα1 is not FDA-approved for any indication. It received Orphan Drug Designation in 1998 for the treatment of DiGeorge anomaly with immune defects, but FDA Orphan Approval Status remains “Not FDA Approved for Orphan Indication” . Tα1 is classified as an FDA Category 2 bulk drug substance, restricting compounding under Section 503A.
Product Specifications
- Form: Lyophilized Powder (Sterile)
- Purity: ≥95–98% (HPLC Verified)
- Molecular Formula: C₁₂₈H₂₁₅N₃₃O₅₅
- Molecular Weight: 3108.28 Da
- CAS Number: 62304-98-7
- Sequence: Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
- Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
- Solubility: Soluble in water (up to 2 mg/mL)
- Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.
Why Choose Thymosin Alpha-1?
Thymosin Alpha-1 offers a well-characterized research tool for studying thymic hormone biology and T-cell-mediated immune regulation. Its defined mechanism involving TLR2/TLR9 agonism, dendritic cell activation, and Th1 cytokine induction provides a rational foundation for experimental design . The peptide has been investigated across diverse clinical contexts—from chronic hepatitis to sepsis to cancer immunotherapy—offering translational relevance. However, researchers should note the significant evidence limitations: the pivotal sepsis Phase 3 trial failed to demonstrate mortality benefit, Cochrane review evidence for hepatitis B is rated very low certainty, and the clinical evidence base is predominantly from non-Western populations with high heterogeneity across trials.



